Carbon-Ion Radiotherapy Induces Ferroptosis in Gastric Cancer via DHODH Suppression

Study Background and Research Question

Gastric cancer remains a significant clinical challenge as the fifth most common cancer and the fourth leading cause of cancer mortality worldwide (source: paper). Many patients are diagnosed at advanced stages, making traditional surgical interventions insufficient for curative treatment. Conventional photon-based radiotherapy, while widely used, often fails to deliver tumoricidal doses to deep-seated or metastatic lesions without incurring unacceptable toxicity to surrounding tissues. Carbon-ion radiotherapy (CIRT), a high linear energy transfer (LET) modality characterized by the Bragg peak phenomenon, offers superior dose localization and biological effectiveness over photon or even proton therapies (source: paper). However, the specific molecular mechanisms underlying CIRT's enhanced efficacy in gastric cancer have not been fully elucidated. The enzyme dihydroorotate dehydrogenase (DHODH), previously implicated in cancer cell survival and therapy resistance, emerged as a candidate regulator of tumor radiosensitivity. Wang and Cai (2025) designed their study to determine whether CIRT mediates its anticancer effects in gastric cancer via DHODH suppression, ferroptosis induction, and immune modulation.

Key Innovation from the Reference Study

The central innovation of this study is the elucidation of a dual mechanism by which CIRT inhibits gastric cancer progression: first, by downregulating DHODH to promote ferroptosis—a regulated, iron-dependent cell death pathway distinct from apoptosis; and second, by facilitating the polarization of tumor-associated macrophages toward an M1 (pro-inflammatory, antitumorigenic) phenotype. These findings provide a compelling mechanistic explanation for CIRT's superior biological effectiveness and suggest that DHODH modulation could be leveraged to further sensitize tumors to high-LET radiotherapy (source: paper).

Methods and Experimental Design Insights

Wang and Cai employed a multi-tiered approach, integrating in vitro cell culture, molecular biology assays, and in vivo xenograft models:

• Cell Lines and CIRT Exposure: Human gastric cancer cell lines (HGC27, AGS) were irradiated with CIRT at doses of 0 Gy (control), 2 Gy, and 4 Gy.
• Cellular Viability and Metastatic Potential: MTT assays quantified cell viability, while Transwell migration and invasion assays assessed metastatic behavior post-irradiation.
• Ferroptosis and DHODH Expression: Western blotting and qRT-PCR evaluated protein and mRNA levels of ferroptosis markers (e.g., ACSL4, GPX4) and DHODH.
• Macrophage Polarization Assessment: Flow cytometry analyzed macrophage phenotype (CD86+CD206−) after exposure to conditioned medium from irradiated cancer cells, coupled with cytokine profiling.
• In Vivo Validation: BALB/c nude mice were xenografted with AGS cancer cells and treated under different conditions (control, CIRT, DHODH overexpression + CIRT) to monitor tumor growth and tissue marker expression.

Protocol Parameters

• cell irradiation (CIRT) | 0 Gy, 2 Gy, 4 Gy | gastric cancer cell lines | Dose-dependent analysis of CIRT on cancer cell fate | paper
• Western blot detection | anti-DHODH, anti-ACSL4, anti-GPX4 antibodies | protein quantification in irradiated cells and xenografts | Key molecular endpoints for ferroptosis and enzyme regulation | paper
• macrophage polarization assay | flow cytometry (CD86, CD206) | tumor-associated macrophages | Quantification of M1 vs. M2 phenotype post-irradiation | paper
• animal model | BALB/c nude mice, subcutaneous AGS injections | in vivo tumor progression | Assessment of CIRT and DHODH modulation in tumor context | paper
• chemiluminescent substrate kit | standard volumes (per manufacturer's protocol) | Western blot and immunoassay detection | Recommended for sensitive HRP-based detection of low-abundance markers | workflow_recommendation

Core Findings and Why They Matter

The study established several mechanistically linked findings (source: paper):

• DHODH Suppression: CIRT led to significant downregulation of DHODH at both transcript and protein levels in gastric cancer cells.
  Implication: Reduced DHODH disrupts pyrimidine biosynthesis and mitochondrial function, sensitizing cancer cells to oxidative stress.
• Ferroptosis Induction: CIRT increased intracellular iron and ROS, upregulated ACSL4 (a ferroptosis promoter), and decreased GPX4 (a ferroptosis inhibitor), confirming ferroptosis activation.
• M1 Macrophage Polarization: Tumor-conditioned medium from CIRT-treated cells induced CD86+CD206− (M1) macrophage polarization and increased M1 cytokine expression, consistent with a shift toward an antitumor immune environment.
• In Vivo Tumor Suppression: In xenograft models, CIRT significantly reduced tumor growth; this effect was diminished when DHODH was overexpressed, confirming its regulatory role.

These findings advance the field by directly linking high-LET radiotherapy to ferroptosis and immune reprogramming via a specific metabolic target (DHODH). This dual mechanism may help overcome the radioresistance and immunosuppression characteristic of advanced gastric cancers.

Comparison with Existing Internal Articles

Recent internal resources provide complementary context for these discoveries:

• "Carbon-Ion Radiotherapy Induces Ferroptosis via DHODH Suppression in Gastric Cancer" provides an overview of the same mechanistic insights, emphasizing the translational relevance of targeting DHODH to sensitize tumors to CIRT.
• "ECL Chemiluminescent Kits: Accelerating Translational Oncology" details how chemiluminescent substrate kits, such as the APExBIO ECL Chemiluminescent Substrate Detection Kit, facilitate the detection of molecular markers involved in ferroptosis and immune modulation, supporting robust preclinical oncology workflows.
• "ECL Chemiluminescent Substrate Detection Kit: Optimized Workflows" discusses methodological best practices for sensitive Western blot chemiluminescence detection, a critical component in the molecular analyses described by Wang and Cai.

Together, these resources highlight a convergence of advanced radiotherapy modalities and optimized molecular detection platforms in modern cancer research.

Limitations and Transferability

While the study provides compelling evidence for CIRT-induced ferroptosis and immune modulation in gastric cancer, several limitations remain:

• The findings are primarily based on human cancer cell lines and immunodeficient mouse models; immune interactions may differ in fully immunocompetent systems.
• DHODH's role as a radiosensitizer may vary across tumor types and microenvironmental contexts.
• The clinical feasibility of combining DHODH modulation with CIRT requires further preclinical and translational validation.

Nevertheless, the protocol and mechanistic framework developed by Wang and Cai could be adapted to other tumor models where ferroptosis and macrophage polarization are relevant.

Research Support Resources

For researchers aiming to replicate or extend these findings, sensitive detection of ferroptosis markers and immune regulators is essential. The ECL Chemiluminescent Substrate Detection Kit (SKU K1129) from APExBIO provides robust HRP-based chemiluminescence suitable for Western blot and immunoassay workflows. This chemiluminescent substrate kit enables the detection of low-abundance proteins, such as DHODH, ACSL4, and GPX4, thereby supporting high-resolution analysis of ferroptosis and immune pathways (workflow_recommendation). For further methodological guidance, internal resources on ECL-based detection and translational oncology workflows may be consulted.